Precipio Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Precipio stock.
View analyst ratings for Precipio or view top-rated stocks.

Wall Street analysts have given Precipio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Precipio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Precipio is scheduled to release its next quarterly earnings announcement on Monday, May 17th 2021.
View our earnings forecast for Precipio.

Precipio, Inc. (NASDAQ:PRPO) announced its quarterly earnings data on Thursday, August, 23rd. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $1.93 by $2.08. The biotechnology company earned $0.82 million during the quarter. Precipio had a negative trailing twelve-month return on equity of 98.29% and a negative net margin of 258.88%.
View Precipio's earnings history.

Precipio's stock was trading at $1.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRPO shares have increased by 226.5% and is now trading at $3.82.
View which stocks have been most impacted by COVID-19.

Shares of Precipio reverse split before market open on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

1 brokerages have issued twelve-month price targets for Precipio's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Precipio's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 83.2% from the stock's current price.
View analysts' price targets for Precipio or view top-rated stocks among Wall Street analysts.

Some companies that are related to Precipio include Harvard Bioscience (HBIO), EyePoint Pharmaceuticals (EYPT), Scientific Industries (SCND), Astrotech (ASTC), BioForce Nanosciences (BFNH), HTG Molecular Diagnostics (HTGM), Pressure BioSciences (PBIO), Arrayit (ARYC), DiaSys (DYXC), Orthometrix (OMRX) and PositiveID (PSID).
View all of PRPO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Inpixon (INPX) and Jaguar Health (JAGX).

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

Precipio's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.85%) and Geode Capital Management LLC (0.75%). Company insiders that own Precipio stock include Ahmed Zaki Sabet and Ilan Danieli.
View institutional ownership trends for Precipio.

PRPO stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Geode Capital Management LLC. Company insiders that have bought Precipio stock in the last two years include Ahmed Zaki Sabet, and Ilan Danieli.
View insider buying and selling activity for Precipio or or view top insider-buying stocks.

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRPO stock can currently be purchased for approximately $3.82.

Precipio has a market capitalization of $69.27 million and generates $3.13 million in revenue each year.

Precipio employs 54 workers across the globe.

The official website for Precipio is www.precipiodx.com.

Precipio is headquartered at 4 Science Park, New Haven CT, 06511.

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at (203) 787-7888 or via email at [email protected]